ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GERN vs CLYM // 10Y YIELD & FRED MACRO BETA

Geron Corporation (NASDAQ) VS. Climb Bio Inc. (NASDAQ) • 15-METRIC TALLY: GERN 1 — CLYM 3
■ METRIC PARITY
macro-sensitivity
—
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GERN VS. CLYM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GERN CLYM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -20.20% -35.00% +14.80 GERN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -18.27% -9.19% -9.08 CLYM /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.4 44.2 -16.80 CLYM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $574.6M $588.7M -$14.1M CLYM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GERN REV CLYM REV GERN GROSS % CLYM GROSS % GERN FCF CLYM FCF
FY 2025 $192.0M $190.1M — — -$111.0M -$54.5M
FY 2024 $486.4M $229.7M — — -$219.3M -$15.6M
FY 2023 $237.0K $112.8M — — -$167.7M -$20.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GERN // BETA —
CLYM // BETA —